PND35 Modeling The Economic Impact Of Incorporating AbobotulinumtoxinA Into An Institutional Formulary For FDA-Approved Indications

Abstract

Authors

J. Mittler N. Danchenko J. Bouchard

Full Text Cite This Article
Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×